Verrica Pharmaceuticals Inc. – NASDAQ:VRCA
Verrica Pharmaceuticals stock price today
$6.12
+5.43
+794.34%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in about 9 hours
Verrica Pharmaceuticals stock price monthly change
-91.97%
month
Verrica Pharmaceuticals stock price quarterly change
-91.97%
quarter
Verrica Pharmaceuticals stock price yearly change
-90.43%
year
Verrica Pharmaceuticals key metrics
Market Cap | 62.49M |
Enterprise value | 182.14M |
P/E | -8.74 |
EV/Sales | 20.16 |
EV/EBITDA | -8.47 |
Price/Sales | 23.79 |
Price/Book | 5.36 |
PEG ratio | -0.19 |
EPS | -1.75 |
Revenue | 8.91M |
EBITDA | -73.41M |
Income | -80.73M |
Revenue Q/Q | 10240.54% |
Revenue Y/Y | 3.18% |
Profit margin | -271.11% |
Oper. margin | -235.78% |
Gross margin | -4.9% |
EBIT margin | -235.78% |
EBITDA margin | -823.66% |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeVerrica Pharmaceuticals stock price history
Verrica Pharmaceuticals stock forecast
Verrica Pharmaceuticals financial statements
| Jun 2023 | 182K | -10.99M | -6038.46% |
|---|---|---|---|
| Sep 2023 | 2.91M | -24.80M | -850.26% |
| Dec 2023 | 1.98M | -24.61M | -1238.13% |
| Mar 2024 | 3.82M | -20.33M | -531.39% |
| 2025 | 72.08M | -42.84M | -59.43% |
|---|---|---|---|
| 2026 | 155.21M | 21.07M | 13.58% |
| 2027 | 216.58M | 21.46M | 9.91% |
| 2028 | 279.59M | 56.98M | 20.38% |
Analysts Price target
Financials & Ratios estimates
| Jun 2023 | 62201000 | 6.80M | 10.93% |
|---|---|---|---|
| Sep 2023 | 97148000 | 54.84M | 56.46% |
| Dec 2023 | 81597000 | 61.83M | 75.78% |
| Mar 2024 | 66311000 | 64.79M | 97.72% |
| Jun 2023 | -4.66M | -59K | -84K |
|---|---|---|---|
| Sep 2023 | -14.81M | -65K | 44.04M |
| Dec 2023 | -14.73M | -227K | 197K |
| Mar 2024 | -19.94M | 0 | -661K |
Verrica Pharmaceuticals alternative data
| Aug 2023 | 22 |
|---|---|
| Sep 2023 | 22 |
| Oct 2023 | 22 |
| Nov 2023 | 22 |
| Dec 2023 | 22 |
| Jan 2024 | 22 |
| Feb 2024 | 22 |
| Mar 2024 | 100 |
| Apr 2024 | 100 |
| May 2024 | 100 |
| Jun 2024 | 100 |
| Jul 2024 | 100 |
Verrica Pharmaceuticals other data
32.84%
+0.30%
of VRCA is owned by hedge funds
8.88M
-71.08K
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Dec 2023 | 2060199 | 0 |
| Jul 2024 | 0 | 98446 |
| Aug 2024 | 0 | 146623 |
| Nov 2024 | 48651681 | 0 |
| Patent |
|---|
Application Filling date: 10 Sep 2021 Issue date: 30 Dec 2021 |
Application Filling date: 27 May 2021 Issue date: 16 Dec 2021 |
Grant Filling date: 20 Jan 2016 Issue date: 9 Nov 2021 |
Grant Utility: Treatment of cutaneous disorders Filling date: 6 Jun 2018 Issue date: 19 Oct 2021 |
Grant Filling date: 21 Aug 2014 Issue date: 6 Jul 2021 |
Application Filling date: 15 Jun 2018 Issue date: 13 May 2021 |
Application Filling date: 17 Aug 2020 Issue date: 11 Mar 2021 |
Grant Design: Applicator Filling date: 15 Jun 2017 Issue date: 27 Oct 2020 |
Application Filling date: 4 Oct 2018 Issue date: 27 Aug 2020 |
Grant Filling date: 17 Dec 2015 Issue date: 18 Aug 2020 |
| Quarter | Transcript |
|---|---|
| Q1 2024 13 May 2024 | Q1 2024 Earnings Call Transcript |
| Q4 2023 29 Feb 2024 | Q4 2023 Earnings Call Transcript |
| Q3 2023 9 Nov 2023 | Q3 2023 Earnings Call Transcript |
| Insider | Compensation |
|---|---|
| Mr. Ted White (1965) Pres, Chief Executive Officer & Director | $725,850 |
| Dr. Gary Goldenberg M.D. (1977) Chief Medical Officer | $571,570 |
-
What's the price of Verrica Pharmaceuticals stock today?
One share of Verrica Pharmaceuticals stock can currently be purchased for approximately $6.12.
-
When is Verrica Pharmaceuticals's next earnings date?
Unfortunately, Verrica Pharmaceuticals's (VRCA) next earnings date is currently unknown.
-
Does Verrica Pharmaceuticals pay dividends?
No, Verrica Pharmaceuticals does not pay dividends.
-
How much money does Verrica Pharmaceuticals make?
Verrica Pharmaceuticals has a market capitalization of 62.49M and it's past years’ income statements indicate that its last revenue has decreased compared to the previous period by 43.27% to 5.12M US dollars.
-
What is Verrica Pharmaceuticals's stock symbol?
Verrica Pharmaceuticals Inc. is traded on the NASDAQ under the ticker symbol "VRCA".
-
What is Verrica Pharmaceuticals's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Verrica Pharmaceuticals?
Shares of Verrica Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Verrica Pharmaceuticals's key executives?
Verrica Pharmaceuticals's management team includes the following people:
- Mr. Ted White Pres, Chief Executive Officer & Director(age: 60, pay: $725,850)
- Dr. Gary Goldenberg M.D. Chief Medical Officer(age: 48, pay: $571,570)
-
How many employees does Verrica Pharmaceuticals have?
As Jul 2024, Verrica Pharmaceuticals employs 100 workers.
-
When Verrica Pharmaceuticals went public?
Verrica Pharmaceuticals Inc. is publicly traded company for more then 7 years since IPO on 15 Jun 2018.
-
What is Verrica Pharmaceuticals's official website?
The official website for Verrica Pharmaceuticals is verrica.com.
-
Where are Verrica Pharmaceuticals's headquarters?
Verrica Pharmaceuticals is headquartered at 44 West Gay Street, West Chester, PA.
-
How can i contact Verrica Pharmaceuticals?
Verrica Pharmaceuticals's mailing address is 44 West Gay Street, West Chester, PA and company can be reached via phone at +48 44533300.
Verrica Pharmaceuticals company profile:
Verrica Pharmaceuticals Inc.
verrica.comExchange:
NASDAQ
Full time employees:
100
Industry:
Biotechnology
Sector:
Healthcare
Verrica Pharmaceuticals Inc., a dermatology therapeutics company, develops and commercializes treatments for people with skin diseases in the United States. The company's lead product candidate includes VP-102 for the treatment of molluscum contagiosum; that has completed Phase II clinical trial for the treatment of external genital warts; and which is in Phase II clinical trial for treating common warts. It is also developing cantharidin-based product candidate, VP-103 for treating plantar warts. The company has a license and collaboration agreement with Torii Pharmaceutical Co., Ltd. for the development and commercialization of its product candidates for the treatment of molluscum contagiosum and common warts in Japan, including VP-102; and a license agreement with Lytix Biopharma AS to develop and commercialize LTX-315 for dermatological oncology indications. Verrica Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in West Chester, Pennsylvania.
44 West Gay Street
West Chester, PA 19380
West Chester, PA 19380
CIK: 0001660334
ISIN: US92511W1080
CUSIP: 92511W108
